Vibrio cholerae Vaccines

Creative Biolabs is a world leader in the field of bacterial vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against cholera caused by Vibrio cholerae and guarantee the finest results for our customers all over the world.

Vibrio cholerae Vaccines - Creative Biolabs

Cholera is a life-threatening secretory diarrhoeal illness associated with the rapid onset of dehydration and hypovolemia caused by the bacterium Vibrio cholerae (V. cholerae). The bacterium is a Gram-negative, halophilic, highly motile, and comma-shaped rod bacillus belonging to the family Vibrionaceae. The strains of V. cholerae, which belongs to serogroups O1 and O139, are capable of causing epidemic cholera. Cholera is characterized by numerous, voluminous watery stools, often accompanied by vomiting, and resulting in hypovolemic shock and acidosis. The disease is transmitted by the fecal-oral route and is most common in places with poor sanitation, crowding, war, and famine.

Oral Cholera Vaccines

Several oral cholera vaccines are available and play an important role in outbreak prevention and long-term control of cholera. A single-dose live oral cholera vaccine can reduce the chance of severe diarrhea in people by 90% at 10 days after vaccination and by 80% at 3 months after vaccination. Other oral inactivated or non-live cholera vaccines are also available and the duration of protection is two years in adults and 6 months in children aged 2-5 years. Oral vaccines are safe in pregnancy and in those with poor immune function and are licensed for use in more than 60 countries.

Subunit Cholera Vaccine

A novel cholera subunit vaccine development is based on the V. cholerae colonization, pathogenesis, and the human immune response to cholera. There is a strategy that utilizes either carbohydrate epitopes bound to carrier proteins, or multiple virulence factors and a toxoid to achieve long-lasting immunity. Individual antibodies (Abs) to V. cholerae LPS and 3 colonization factors are protective in animal models. These V. cholerae virulence factors will be used to configure a cholera subunit vaccine to induce a concentrated immune response to the critical first step in V. cholerae pathogenesis. The subunit cholera vaccine was composed of 4 protective V. cholerae colonization/adhesion factors which will induce protective immunity with 1 dose. Detoxified Inaba LPS will be conjugated to one of three virulence factors: Toxin Co-Regulated pilus A (TcpA), TcpF or chitin-binding protein A (CBP-A). Carrier-specific T cell will help enhance the anti-LPS response and help for induction of protective carrier-specific Abs.

Conjugate Cholera Vaccine

A new conjugate vaccine for cholera has been developed which includes a new method to conjugate the O-specific polysaccharide-core part of the bacterial lipopolysaccharide and protein subcomponents. Conventional technology has entailed chemical treatment of both components to introduce linkers, which made them amenable for covalent linking. The new method simplifies production by utilizing squaric acid chemistry for conjugating the free amine-containing species directly to amine-containing species without prior modification of either component. While demonstrated in this new cholera prototype vaccine, the technology is envisioned as generally applicable, thereby streamlining a complex production process.

Outer Membrane-Based Vaccine

The development of a novel cholera vaccine is comprised of outer membrane vesicles (OMVs) from V. cholerae that are spherical blebs naturally shed by Gram-negative bacteria, a lipid bilayer containing outer membrane proteins and other periplasmic components. Data have shown that immunization of adult mice with OMVs leads to the production of antibodies specific to V. cholerae proteins. This protection can extend long term as pups born 84 days post-immunization were still protected from infection. OMV vaccines can be delivered via multiple methods including the intranasal, intragastric, or intraperitoneal routes, with similar efficacy.

Creative Biolabs is a highly proactive, robust, and diversified company with a strong, scientifically-proven background of bacterial vaccine development. We have experts who are able to help you with the vaccine development against cholera caused by Vibrio cholerae. If you are interested in our services, please contact us for more details.

Our services are for research use only. We do not provide services directly to individuals.

Online Inquiry

*E-mail Address:
*Products or Services Interested:
Project Description:
*Verification Code:
Verification code
Click image to refresh the verification code.


45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-466-5530
Fax: 1-631-207-8356
UK - Germany

Follow us on

facebook   twitter   linked   blog

Shopping Basket